More on INCY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $108.53 |
|
|||
| Open | $108.53 | ||||
| 52 Wk High | $118.49 | ||||
| 52 Wk Low | $55.00 | ||||
| Day High | $108.53 | ||||
| Day Low | $108.53 | ||||
| P/E | N/A | ||||
| EPS | $-0.56 | ||||
| Volume | 7,048 | ||||
- Mirum and Incyte report positive phase 2 results for FOP treatment
- Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
- NASDAQ: INCY shows 25% reduction in disease progression risk in lymphoma study
- Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
- Form 4 INCYTE CORP For: Jun 08 Filed by: BAKER BROS. ADVISORS LP
- Incyte (INCY) PT Raised to $136 at Guggenheim
- Form 4 INCYTE CORP For: Jun 08 Filed by: HARRIGAN EDMUND
- Form 4 INCYTE CORP For: Jun 08 Filed by: Clancy Paul J
- Form 4 INCYTE CORP For: Jun 08 Filed by: FOUSE JACQUALYN A
- Form 4 INCYTE CORP For: Jun 08 Filed by: BIENAIME JEAN JACQUES
Entities mentioned with INCY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
